Bone signaling pathways and treatment of osteoporosis

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 6, 2009, Pages 639-650

  Gogakos, Apostolos I ^a   Cheung, Moira S ^a   Bassett, J H Duncan ^a   Williams, Graham R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Anabolic; Antiresorptive; Bone remodeling; Osteoblast; Osteoclast; Osteocytes; Osteoporosis; RANKL OPG RANK; Wnt signaling

Indexed keywords

10,11 DIHYDRO 3 [3 (2 PYRIDINYLAMINO)PROPOXY] 5H DIBENZO[A,D]CYCLOHEPTENE 10 ACETIC ACID; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALENDRONIC ACID; AMG 785; BALICATIB; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; DENOSUMAB; DICKKOPF 1 PROTEIN; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L 000845704; LY 603281 31 8; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN INHIBITOR; RALOXIFENE; RISEDRONIC ACID; RONACALERET; SB 265213; SCLEROSTIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; WNT PROTEIN; ZOLEDRONIC ACID;

APOPTOSIS; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; ENTEROCHROMAFFIN CELL; ESTROGEN THERAPY; GASTROINTESTINAL SYMPTOM; GENE ACTIVATION; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LOSS OF FUNCTION MUTATION; MINERALIZATION; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TRANSCRIPTION REGULATION; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 70449972209     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.38     Document Type: Review

References (116)

1. Kanis JA; on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level: technical report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. University of Sheffield, Sheffield, UK (2007). • Detailed review of osteoporosis epidemiology and fracture risk assessment.
2. Sambrook P, Cooper C. Osteoporosis. Lancet 367(9527), 2010-2018 (2006).
3. Lewiecki ME. Emerging drugs for postmenopausal osteoporosis. Expert Opin. Emerg. Drugs 14(1), 129-144 (2009).
4. Seeman E, Delmas PD. Bone Quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250-2261 (2006). • Physiology and pathophysiology of bone metabolism.
5. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. DOI: 10.1007/s00198-009-0930-1 (2009) (Epub ahead of print).
6. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone 42, 606-615 (2008).
7. Bilezikian JP, Matsumoto T, Bellido T et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J. Bone Miner. Res. 24(3), 373-385 (2009).
8. Han Y, Cowin SC, Schaffler MB, Weinbaum S. Mechanotransduction and strain amplification in osteocyte cell processes. Proc. Natl Acad. Sci. USA 101, 16689-16694 (2004). (Pubitemid 39557774)
9. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J. Cell. Sci. 113, 377-381 (2000).
10. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N. Engl. J. Med. 351, 2839-2849 (2004).
11. Martin TJ, Sims NA, Ng KW. Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos. Int. 19, 1125-1138 (2008).
12. Koshla S, Westendorf JJ, Ousler MJ. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421-428 (2008).
13. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905-916 (2007). • Very good review of the biological basis of many emerging anabolic agents.
14. Kearns AE et al. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29, 155-192 (2008). • RANK/RANKL/osteoprotegerin involvement in regulation of bone remodeling.
15. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligandfor osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998). (Pubitemid 128616230)
16. Burgess TL, Qian Y, Kaufman S et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell. Biol. 145, 527-538 (1999). (Pubitemid 29215717)
17. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor κB in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214 (2003).
18. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998). (Pubitemid 28180851)
19. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649 (2003).
20. Baron R, Rawadi G. Minireview: targeting the Wnt/b-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148(6), 2635-2643 (2007). • Elucidation of Wnt signalling pathway and its implication in regulation of bone formation.
21. Sobacchi C, Frattini A, Guerrini MM et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39(8), 960-962 (2007). (Pubitemid 47185178)
22. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S et al. Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. 358(22), 2355-2365 (2008). (Pubitemid 351749159)
23. Whyte MP, Obrecht SE, Finnegan PM et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347(3), 175-184 (2002).
24. Cundy T, Hegde M, Naot D et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11(18), 2119-2127 (2002).
25. Arko B, Prezelj J, Komel R, Kocijancic A, Hudler P, Marc J. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 87(9), 4080-4084 (2002).
26. Venta PJ, Welty RJ, Johnson TM, Sly WS, Tashian RE. Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His-Tyr): complete structure of the normal human CA II gene. Am. J. Hum. Genet. 49(5), 1082-1090 (1991).
27. Kornak U, Kasper D, Bösl MR et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104(2), 205-215 (2001). (Pubitemid 32174837)
28. Cleiren E, Bénichou O, Van Hul E et al. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum. Mol. Genet. 10(25), 2861-2867 (2001).
29. Chalhoub N, Benachenhou N, Rajapurohitam V et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat. Med. 9(4), 399-406 (2003). (Pubitemid 36460073)
30. Frattini A, Orchard PJ, Sobacchi C et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat. Genet. 25(3), 343-346 (2000).
31. Kornak U, Schulz A, Friedrich W et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum. Mol. Genet. 9(13), 2059-2063 (2000).
32. Van Wesenbeeck L, Odgren PR, Coxon FP et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J. Clin. Invest. 117(4), 919-930 (2007).
33. Del Fattore A, Fornari R, Van Wesenbeeck L et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J. Bone Miner. Res. 23(3), 380-391 (2008).
34. Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4), 513-523 (2001). (Pubitemid 33152786)
35. Boyden LM, Mao J, Belsky J et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521 (2002). (Pubitemid 34755690)
36. Little RD, Carulli JP, Del Mastro RG et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11-19 (2002).
37. Zhang Y, Wang Y, Li X et al. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol. Cell. Biol. 24(11), 4677-4684 (2004).
38. Ellies DL, Viviano B, McCarthy J et al. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21(11), 1738-1749 (2006).
39. Ferrari SL, Deutsch S, Choudhury U et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am. J. Hum. Genet. 74(5), 866-875 (2004). (Pubitemid 38568961)
40. Richards JB, Rivadeneira F, Inouye M et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371(9623), 1505-1512 (2008).
41. Brunkow ME, Gardner JC, Van Ness J et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68(3), 577-589 (2001).
42. Balemans W, Patel N, Ebeling M et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39(2), 91-97 (2002).
43. Uitterlinden AG, Arp PP, Paeper BW et al. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am. J. Hum. Genet. 75(6), 1032-1045 (2004).
44. McClung MR. Bisphosphonates. Endocrinol. Metab. Clin. North Am. 32, 253-271 (2003).
45. Russell RG, Xia Z, Dunford JE et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. NY Acad. Sci. 1117, 209-257 (2007).
46. Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24), 2927-2938 (2006).
47. Goh SK, Yang KY, Koh JS et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. Br. 89(3), 394-1353 (2007).
48. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39(2), 224-231 (2008).
49. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J. Bone Miner. Res. 22(10), 1479-1491 (2007).
50. Wells GA, Cranney A, Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 23(1), CD001155 (2008).
51. Wells G, Cranney A, Peterson J et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 23(1), CD004523 (2008).
52. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann NY Acad. Sci. 1068, 173-179 (2006). (Pubitemid 43824147)
53. Nakamura T, Imai Y, Matsumoto T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of fas ligand in osteoclasts. Cell 130, 811-823 (2007). (Pubitemid 47332572)
54. Charatcharoenwitthaya N, Khosla S. Atkinson EJ et al. Effect of blockade of TNF-α and interleukin-1 action on bone resorptionin early postmenopausal women. J. Bone Miner. Res. 22, 724-729 (2007). (Pubitemid 351339101)
55. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289(24), 3243-3253 (2003).
56. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290(13), 1729-1738 (2003). (Pubitemid 37430623)
57. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
58. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004). (Pubitemid 38489892)
59. Barrett-Conno E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355(2), 125-137 (2006). (Pubitemid 44050394)
60. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13, 387-403 (2007).
61. Adami S, Supronik J, Hala T et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J. Bone Miner. Res. 21, S24 (2006). • Evidence that cathepsin K inhibition reduces bone resorption.
62. Deal C. Potential new drug targets for osteoporosis. Nat. Clin. Pract. Rheumatol. 5(1), 20-27 (2009).
63. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16(2), 348-360 (2001). (Pubitemid 32105416)
64. Body JJ, Greipp P, Coleman RE et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(3 Suppl.), 887-892 (2003).
65. Boyce BF, Xing L,. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473(2), 139-146 (2008).
66. Hamdy NA. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc.) 44, 7-21 (2008).
67. Lewiecki EM, Miller PD, McClung MR et al. Two-year treatment with denosumab (AMG 162) in a randomized Phase 2 study of postmenopausal women with low BMD. J. Bone Miner. Res. 22(12), 1832-1841 (2007).
68. McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354(8), 821-831 (2006).
69. Brown JP, Prince RL, Deal C et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, Phase 3 trial. J. Bone Miner. Res. 24(1), 153-161 (2009). •• Phase III study of the skeletal effects of RANKL inhibition with a monoclonal antibody (denosumab) - comparison with bisphosphonates.
70. Miller PD, Bolognese MA, Lewiecki EM et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded Phase 2 clinical trial. Bone 43(2), 222-229 (2008).
71. Kendler DL, Benhamou CL, Brown JP et al. Effects of denosumab vs alendronate on bone mineral density (BMD), bone turnover markers (BTM), and safety in women previously treated with alendronate. J. Bone Miner. Res. 23(Suppl.), S473 (2008).
72. Cummings S, McClung MR, Christiansen C et al. A Phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM trial. J. Bone Miner. Res. 23, (2008) (Abstract 1286).
73. Whyte MP. The long and the short of bone therapy. N. Engl. J. Med. 354(8), 860-863 (2006).
74. Kim H, Choi HK, Shin JH et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J. Clin. Invest. 119(4), 813-825 (2009).
75. Missbach M, Jeschke M, Feyen J et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24(5), 437-449 (1999). (Pubitemid 29234132)
76. Lark MW, Stroup GB, Hwang SM et al. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J. Pharmacol. Exp. Ther. 291(2), 612-617 (1999).
77. Murphy MG, Cerchio K, Stoch SA et al. Effect of L-000845704, an avb3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 90(4), 2022-2028 (2005). (Pubitemid 40586234)
78. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40(6), 1434-1446 (2007).
79. McClung MR, San Martin J, Miller PD et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165(15), 1762-1768 (2005).
80. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19), 1434-1441 (2001).
81. Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146(5), 326-339 (2007).
82. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J. Bone Miner. Res. 22(2), 334 (2007). (Pubitemid 46167804)
83. Brown M. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell. Biochem. 45, 139-167 (2007).
84. Balan G, Bauman J, Bhattacharya S et al. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg. Med. Chem. Lett. 19(12), 3328-3332 (2009).
85. Kulkarni NH, Onyia JE, Zeng Q et al. Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J. Bone Miner. Res. 21, 910-920 (2006). (Pubitemid 43787998)
86. Clement-Lacroix P, Ai M, Morvan F et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl Acad. Sci. USA 102, 17406-17411 (2005).
87. Vestergaard P, Rejnmark L, Mosekilde L. Reduced relative risk of fractures among users of lithium. Calcif. Tissue Int. 77, 1-8 (2005). (Pubitemid 41504166)
88. Wilting I, de Vries F, Thio BM et al. Lithium use and the risk of fractures. Bone 40, 1252-1258 (2007).
89. Morvan F, Boulukos K, Clement-Lacroix P et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934-945 (2006). (Pubitemid 43788000)
90. Li J, Sarosi I, Cattley RC et al. Dkk1- mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754-766 (2006). (Pubitemid 44311706)
91. Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40(2), 485-492 (2007).
92. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494 (2003). (Pubitemid 38010074)
93. Heider U, Kaiser M, Mieth M et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur. J. Haematol. 82(1) 31-38 (2009).
94. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109(5), 2106-2111 (2007). (Pubitemid 46348212)
95. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2), 371-379 (2009).
96. Robling AG, Bellido T, Turner CH. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J. Musculoskelet. Neuronal Interact. 6, 354 (2006). (Pubitemid 46099713)
97. Ominsky M, Warmongton KS, Asuncion FJ et al. Sclerostin monoclonal antibody treatment increases bone strength in aged osteopenic ovariectomized rats. J. Bone Miner. Res. 21, S44 (2006).
98. Poole KE, van Bezooijen RL, Loveridge N et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842-1844 (2005).
99. Li X, Ominsky MS, Warmington KS et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24(4), 578-588 (2009). • Evidence suggestive that sclerostin antagonism has anabolic effects on bone.
100. Reginster JY, Sarlet N, Lejeune E, Leonori L. Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. Curr. Osteoporos. Rep. 3(1), 30-34 (2005).
101. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350(5), 459-468 (2004). • Evidence that strondium ranelate decreases fracture risk in vertebral sites.
102. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90(5), 2816-2822 (2005). (Pubitemid 40686329)
103. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol. Assess. 11(4), 1-134 (2007).
104. Blake GM, Lewiecki EM, Kendler DL et al. A review of strontium ranelate and its effect on DXA scans. J. Clin. Densitom. 10(2), 113-119 (2007).
105. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 104(4), 531-543 (2001).
106. Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100(2) 197-207 (2000).
107. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4(5), 341-348 (2006). (Pubitemid 44645074)
108. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 122(5), 803-815 (2005).
109. Rosen CJ. Bone remodeling, energy metabolism, and the molecular clock. Cell Metab. 7(1), 7-10 (2008). •• Excellent review of the central control of bone remodeling. A detailed view into the interactions between bone physiology and energy metabolism, central neuronal pathways, osteocalcin and serotonin.
110. Sato S, Hanada R, Kimura A et al. Central control of bone remodeling by neuromedin U. Nat. Med. 13(10), 1234-1240 (2007).
111. Elefteriou F, Ahn JD, Takeda S et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434(7032), 514-520 (2005).
112. Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K, Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147(7), 3196-3202 (2006). (Pubitemid 43901110)
113. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130(3), 456-469 (2007). (Pubitemid 47208519)
114. Yadav VK, Ryu JH, Suda N et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135(5), 825-837 (2008).
115. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM, de Vernejoul MC. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J. 22, 418-427 (2008). (Pubitemid 351225578)
116. Rosen CJ. Serotonin rising - the bone, brain, bowel connection. N. Engl. J. Med. 360(10), 957-959 (2009).